CD8A and neoplasm: An inhibition of these molecules, exploiting immune checkpoint inhibitors (CPIs), leads to an enhancement of tumor-directed CD8+ T-cell activity and in part to a reduction of Treg-depended immunosuppression resulting in durable remissions in a subgroup of patients with different tumor types (1, 2).